ProCE Banner Activity

Updated Analysis of Phase III TRIBE2: FOLFOXIRI + Bev → FOLFOXIRI + Bev vs FOLFOX + Bev → FOLFIRI + Bev in Unresectable Metastatic Colorectal Cancer

Slideset Download
Conference Coverage
First-line FOLFOXIRI/bevacizumab followed by retreatment with the same regimen upon progression improved PFS2 compared with sequential FOLFOX/bevacizumab followed by FOLFIRI/bevacizumab in unresectable mCRC.

Released: June 02, 2019

Expiration: May 31, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro